Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
Status:
Withdrawn
Trial end date:
2023-07-30
Target enrollment:
Participant gender:
Summary
This is an open label, Phase IB dose-escalation study of the PI3K inhibitor copanlisib in
combination with romidepsin in patients with relapsed or refractory (R/R) non-Hodgkin
lymphoma (NHL) or Hodgkin lymphoma (HL).
The primary objective of the phase I study is to determine the maximum tolerated dose (MTD),
recommended phase 2 dose (RP2D), and dose limiting toxicities (DLTs) of the combination of
copanlisib and romidepsin in patients with R/R, NHL or HL.